Biotech Values

[poorgradstudent]

>It's clearly a large market and I do agree that there will be room for two JAK inhibitors. I just think given that PFE is so far ahead they'll have first mover advantage and will presumably be able to capture and maintain a larger share of the market compared to LLY/INCY. I guess I'd feel more comfortable about LLY/INCY's share of the market if the market cap were a bit cheaper.<

I guess I don't really understand why INCY's putative splitting of the JAK market in RA makes RIGL's market any bigger?

I think we're both of the mindset that the PFE drug is going to be on market first. Unless RIGL's drug shows head to head superiority, they're going to be placed behind PFE's drug in the treatment hierarchy. The market that falls into RIGL's lap is then not so much bigger than what INCY may be able to garner by sharing the JAK / RA population with PFE.